Drug Name (Brand / Generic)
Orenitram / treprostinil / UT-15C
Orenitram (treprostinil/UT-15C) is indicated for the treatment of pulmonary arterial hypertension (PAH), in World Health Organisation (WHO) Group I patients, to improve exercise capacity. The drug was discovered and developed by United Therapeutics Corporation.
United Therapeutics received approval for marketing Orenitram, from the US Food and Drug Administration (FDA), for the treatment of pulmonary arterial hypertension (PAH) in December 2013.
Pulmonary arterial hypertension (PAH) is characterised by high blood pressure in the arteries. The disease originates when pulmonary arteries and capillaries become narrowed, blocked, or destroyed.
The disease can result in heart failure or decreased tolerance to exercise due to shortness of breath, dizziness and fainting. The principal symptoms of the disease include breathlessness, fatigue, heart failure, and severe restrictions on the exercise capacity.
The disease is estimated to affect 1,000 people every year in the US. The incidence of the disease is 2.4 cases per million people in a year. It is also observed that women are more commonly affected by PAH as they constitute about 60% of the registered cases.
Orenitram contains prostacyclin analogue that works as vasodilator to widen the blood vessels of the pulmonary and systemic arterial vascular beds. The drug also inhibits platelet aggregation, and smooth muscle cell proliferation.
The drug is available for oral administration in 0.125mg, 0.25mg, 1mg and 2.5mg dosage tablets.
FDA approval of Orenitram was based on the results obtained from a phase III clinical trial, known as FREEDOM-M study. It was a randomised, double blind, and parallel assignment, which enrolled 349 PAH patients. The study was conducted between October 2006 and April 2011.
The primary outcome measure of the study was the six-minute walk distance (6MWD) from baseline to week 12. The secondary outcome measures included the 6MWD from base line to weeks 11, eight and six, and clinical worsening assessment.
The study results demonstrated that the patients treated with Orenitram in a twice-daily dose showed improvement in the median six-minute walk distance (6MWD) by +23m when compared with patients receiving only placebo. Common side-effects found in the patients treated with Orenitram during the clinical study included headache, nausea, and diarrhoea.
Another phase III clinical trial, known as FREEDOM-C, was also conducted on Orenitram, across 72 centres worldwide, between October 2006 and December 2010. The randomised, multi centre, double blind and parallel assignment enrolled 354 PAH patients.
The primary outcome measure of the study was the 6MWD from baseline to week 16. The secondary outcome measures included Borg dyspnea score at week 16, clinical worsening assessment at week 16, Dyspnea-fatigue index, and World Health Organization (WHO) Functional classification for PAH.
The study results showed that the patients administered with Orenitram did not show a benefit in exercise with median 6MWD at week 16.
Headquartered at Silver Spring in Maryland, United Therapeutics Corporation is a leading biotechnology company engaged in the manufacturing and marketing of products targeting the unmet medical needs of patients with chronic and fatal conditions.
Supernus Pharmaceuticals entered into a licensing agreement with United Therapeutics for the development of extended release formulation of Orenitram. Under the agreement, Orenitram uses EnSoTrol, an innovative osmotic technology platform developed by Supernus that allows improved solubility and controlled oral delivery of pharmaceutical agents.
The EnSoTrol platform has been designed to offer distinctive release profiles as well as to deal with specific challenges in oral delivery of Orenitram.
Other medications available in the market for the treatment of PAH include Opsumit and Veletri developed by Actelion Pharmaceuticals, and Revatio manufactured by Pfizer.
WAKIX® (pitolisant) is the first and only non-scheduled medication indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS)…
SIMPONI ARIA® (golimumab) is a fully human anti-tumour necrosis factor (TNF) alpha monoclonal antibody. It is indicated for the treatment…
FETROJA® (cefiderocol) is the first approved siderophore cephalosporin antibacterial drug. It is indicated for the treatment of complicated urinary tract…
Enspryng™ (satralizumab-mwge) is the first and only US Food and Drug Administration (FDA)-approved subcutaneous therapy indicated for the treatment of…